SAN LUIS OBISPO, California – November 29, 2010 – FzioMed, Inc. announced a major milestone in sales as the 200,000th unit of Oxiplex left its California manufacturing facility. Outside the U.S., Oxiplex also known as MediShield, is approved for sale in 63 countries including Canada, Australia, South Korea, Brazil and the entire European Union.
“Over the last few years our World Class distributors, which include DePuy Spine and Medtronic, have done an amazing job ensuring that both Oxiplex and MediShield are the premier brands that surgeons trust when using an adhesion barrier after decompression surgery.” said John Krelle, FzioMed President and Chief Executive Officer.
“The market for our products is vast as there are over 800,000 discectomies performed every year. We remain hopeful that the United States will join the list of countries that have already approved the device, so that American patients will be able to benefit from the clinically proven reduction in pain and symptoms that Oxiplex provides.”
Oxiplex is an absorbable gel that is applied to spinal nerve roots and dura during lumbar laminectomy, laminotomy and discectomy procedures. Oxiplex creates a temporary, protective barrier against the damaging effects of excessive fibrosis, inflammation and other irritants that can lead to recurrent postoperative pain. Oxiplex has been shown to improve spine surgery outcomes by significantly reducing postoperative leg pain, back pain and neurological symptoms.
FzioMed is a privately held medical device company developing and commercializing absorbable, surgical biomaterials based on the company’s patented science. FzioMed’s polymer technology has uses in a variety of surgical specialties including orthopedics, spine, gynecology and general surgery.
FzioMed® and Oxiplex® are registered trademarks of FzioMed, Inc.